Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2016 16:12 ET | Source: Dermira, Inc.

Dermira Reports Second Quarter 2016 Financial Results and Provides Corporate Update

Reported Topline Results for Two Late-Stage Clinical ProgramsRaised Approximately $136 Million in Net Proceeds from Follow-on Public OfferingUpdates Guidance for Topline Phase 3 CIMZIA®...
March 14, 2016 07:30 ET | Source: Dermira, Inc.

Dermira’s Co-founder and Chief Medical Officer, Eugene A. Bauer, M.D., Receives Presidential Citation from the American Academy of Dermatology

MENLO PARK, Calif., March 14, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
March 03, 2016 07:30 ET | Source: Dermira, Inc.

Dermira Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update

MENLO PARK, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
March 01, 2016 16:05 ET | Source: Dermira, Inc.

Dermira to Report Fourth Quarter and Full Year 2015 Financial Results

MENLO PARK, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
March 01, 2016 07:30 ET | Source: Dermira, Inc.

Dermira to Present at Cowen and Company 36th Annual Health Care Conference

MENLO PARK, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
February 29, 2016 07:30 ET | Source: Dermira, Inc.

Dermira Completes Patient Enrollment for DRM04 Phase 3 Pivotal Trials in Primary Axillary Hyperhidrosis

MENLO PARK, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
January 08, 2016 01:00 ET | Source: Dermira, Inc.

Dermira Completes Patient Enrollment for Third CIMZIA® (certolizumab pegol) Phase 3 Clinical Trial in Psoriasis Program and Updates Guidance for Release of Topline Data

Enrollment for All Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Plaque Psoriasis Completed Dermira Plans to Announce Topline Data for Phase 3 Trials by End of First Quarter...